skip to the content

Clinical Trials

Alzheimer's Disease - Memantine Study

An Open-Label exploratory study with memantine:  Correlation between proton magnetic resonance spectroscopy, cerebrospinal fluid biomarkers, and cognition in patients with mild to moderate Alzheimer's Disease

Protocol ID

06.02.108T

Protocol Description

The purpose of this study is to gain a better understanding of what happens to brain chemistry and mental ability in patients with moderate Alzheimer's disease who are taking a stable dose of an FDA approved acetylcholinesterase (ACE) inhibitor drug [that is, either donepezil (Aricept®), rivastigimaine (Exelon®) or galantamine (Razadyne®)] and are then given memantine HCl (Namenda™) in addition to their other medication.

Brain chemistry will be evaluated with a type of brain scanning known as magnetic resonance spectroscopy or “MRS” and by testing cerebrospinal fluid (CSF), and mental ability will be evaluated using paper and pencil tests.

Eligibility Criteria

Patients with moderate Alzheimer's disease

Primary Investigator(s)

  • Marc L. Gordon, MD

Contact Information

Erica Christen, RN
(516) 487-3492
Echriste@nshs.edu

Last Update

March 25, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Mental Health:
top
top